Search

Your search keyword '"Gretel Benítez"' showing total 8 results
Start Over Author "Gretel Benítez" Topic business.industry
8 results on '"Gretel Benítez"'

1. Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study

Author

Manuel Cobo, R. López-Castro, Amparo Sanchez-Gastaldo, Alberto Ruano-Ravina, Ana Laura Ortega, Bartomeu Massuti, Anna Estival, Oscar Juan, Enric Carcereny, Gretel Benítez, Mariano Provencio, Diego Pereiro Corbacho, Juana Oramas, Ana Blasco, Joaquín Mosquera-Martínez, Marta Belver, Carlos Guirao-Rubio, María Guirado-Risueño, Joaquim Bosch-Barrera, Edel del Barco Morillo, Jose Manuel Trigo, Delvys Rodriguez-Abreu, Manuel Domine, Carlos Aguado De La Rosa, Virginia Calvo de Juan, [Ruano-Ravina,A] Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain. [Ruano-Ravina,A] Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain. [Ruano-Ravina,A] Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain. [Provencio,M, Calvo de Juan,V] Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain. [Carcereny,E, Estival,A] Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain. [Rodríguez-Abreu,D, Benítez,G] Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. [López-Castro,R, Belver,M] Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Guirado-Risueño,M, Guirao-Rubio,C] Hospital de Elche, Elche, Spain, [Blasco,A] Hospital General de Valencia, Valencia, Spain. [Massutí,B] Hospital Universitario General de Alicante, Alicante, Spain. [Ortega,AL] Servicio de Oncología Médica. Complejo Hospitalario de Jaén, Jaén, Spain. [Cobo,M] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Mosquera-Martínez,J] Hospital Universitario de A Coruña, A Coruña, Spain. [Aguado de la Rosa,C] Department of Oncology, Clínico San Carlos Hospital, Madrid, Spain. [Bosch-Barrera,J] Girona Biomedical Research Institute (IDIBGI), Girona, Spain. [Bosch-Barrera,J] Department of Medical Sciences, Medical School, University of Girona, Girona, Spain. [Bosch-Barrera,J] Medical Oncology, Catalan Institute of Oncology, Hospital Universitari Dr. Josep Trueta, Girona, Catalonia, Spain. [Sánchez-Gastaldo,A] Department of Oncology, Hospital Virgen del Rocío, Seville, Spain. [del Barco Morillo,E] Department of Oncology, Hospital de Salamanca, Slamanca, Spain. [Juan,Ó] Servicio Oncología Médica, Hospital Universitari i Politécnic La Fe, Valencia, Spain. [Dómine,M] Hospital Jiménez Díaz, Madrid, Spain. [Trigo,JM] Servicio de Oncología Médica y Unidad de Fases I, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Pereiro Corbacho,D] Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Oramas,J] Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain., Institut Català de la Salut, [Ruano-Ravina A] Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Santiago de Compostela, Spain. Consortium for Biomedical Research in Epidemiology & Public Health (CIBER en Epidemiología and Salud Pública/CIBERESP), Madrid, Spain. Health Research Institute of Santiago de Compostela (Instituto de Investigación Sanitaria de Santiago de Compostela - IDIS), Santiago de Compostela, Spain. [Provencio M, Calvo de Juan V] Department of Oncology, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain. [Carcereny E, Estival A] Medical Oncology Department, Catalan Institute of Oncology, Badalona- Germans Trias i Pujol Hospital B-ARGO group, Barcelona, Spain. [Rodríguez-Abreu D, Benítez G] Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain. [López Castro R, Belver M] Servicio de Oncología, Sección de oncología médica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Guirado Risueño M, Guirao-Rubio C] Hospital de Elche, Elche, Spain.[ Blasco A] Hospital General de Valencia, Valencia, Spain. [Massutí B] Hospital Universitario General de Alicante, Alicante, Spain. [Ortega Granados AL] Servicio de Oncología Médica. Complejo Hospitalario de Jaén, Jaén, Spain. [Cobo M] Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.[ Mosquera-Martínez J] Hospital Universitario de A Coruña, A Coruña, Spain. [Aguado C] Department of Oncology, Clínico San Carlos Hospital, Madrid, Spain. [Bosch-Barrera J] Girona Biomedical Research Institute (IDIBGI), Girona, Spain. Department of Medical Sciences, Medical School, University of Girona, Girona, Spain. Medical Oncology, Catalan Institute of Oncology, Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Sanchez Gastaldo A] Department of Oncology, Hospital Virgen del Rocío, Seville, Spain. [Del Barco Morillo E] Department of Oncology, Hospital de Salamanca, Salamanca, Spain. [Juan O] Servicio Oncología Médica, Hospital Universitari i Politécnic La Fe, Valencia, Spain. [Dómine M] Hospital Jiménez Díaz, Madrid, Spain. [Trigo J] Servicio de Oncología Médica y Unidad de Fases I, Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Pereiro Corbacho D] Hospital Universitario Álvaro Cunqueiro, Vigo, Spain. [Oramas J] Hospital Universitario de Canarias, Santa Cruz Tenerife, Spain, and Hospital Universitari de Girona Dr Josep Trueta

Subjects
Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Signs and Symptoms, Digestive::Anorexia [Medical Subject Headings], Carcinoma pulmonar de células pequeñas, Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Tobacco Use::Smoking [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Pulmons - Càncer, Weight loss, Lung neoplasms, Other subheadings::/diagnosis [Other subheadings], Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [Medical Subject Headings], Fumar, Fumadors, Stage (cooking), conducta y mecanismos de la conducta::conducta::fumar [PSIQUIATRÍA Y PSICOLOGÍA], Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [Medical Subject Headings], Smoking, Small cell lung cancer (SCLC), Disciplines and Occupations::Natural Science Disciplines::Physics::Electronics [Medical Subject Headings], Anorexia, Oncology, Adenocarcinoma, Smoking status, Original Article, Sex, medicine.symptom, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Asthenia [Medical Subject Headings], Behavior and Behavior Mechanisms::Behavior::Smoking [PSYCHIATRY AND PSYCHOLOGY], medicine.medical_specialty, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [DISEASES], Neoplasias pulmonares, Otros calificadores::/diagnóstico [Otros calificadores], Check Tags::Male [Medical Subject Headings], Sexo, Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms [Medical Subject Headings], enfermedades respiratorias::enfermedades respiratorias::neoplasias del tracto respiratorio::neoplasias pulmonares [ENFERMEDADES], Internal medicine, medicine, Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings], Lung cancer, business.industry, Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Demography [Medical Subject Headings], Cancer, medicine.disease, Astenia, Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Sex Factors [HEALTH CARE], Check Tags::Female [Medical Subject Headings], Asthenia, Diferències entre sexes, Symptoms, calidad, acceso y evaluación de la atención sanitaria::calidad de la atención sanitaria::factores epidemiológicos::factores sexuales [ATENCIÓN DE SALUD], Síntomas, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries [Medical Subject Headings], Stage iv, business
Abstract

Càncer de pulmó; Fumar; Diferències entre sexes Cancer de pulmón; Fumar; Diferencias entre sexos Lung neoplasms; Smoking; Sex Factors Background: Lung cancer causes approximately 25% of all cancer deaths. Despite its relevance, few studies have analyzed differences by sex at the time of diagnosis in terms of symptoms, stage, age or smoking status. We aim to assess if there are differences between men and women on these characteristics at diagnosis. Methods: We analyzed the Thoracic Tumour Registry (TTR), sponsored by the Spanish Lung Cancer Group using a case-series design. This is a nationwide registry of lung cancer cases which started recruitment in 2016. For each case included, clinicians fulfilled an electronic record registering demographic data, symptoms, exposure to lung cancer risk factors, and treatment received in detail. We compared men and women using descriptive statistics. Results: A total of 13,590 participants took part in this study, 25.6% women. Women were 4 years younger than men (64 vs. 69), and men had smoked more frequently. Adenocarcinoma was the most frequent histological type in both sexes. Stage IV at diagnosis was 50.8% in women compared to 43.6% in men. Weight loss/anorexia/asthenia was the most frequent symptom in both sexes and there were no differences in the number of symptoms at diagnosis. There were no relevant differences in the frequency or number of symptoms by sex when non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) were analyzed separately. Smoking status did not appear to cause different lung cancer presentation in men compared to women. Conclusions: There seems to be no differences in lung cancer characteristics by sex at the time at diagnosis on stage, specific symptoms or number of symptoms. This research received funding from the Spanish Lung Cancer Group

Published
2021

2. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

Author

Ana Royuela, Maria Saigi, Blanca de Vega, Edel del Barco, Delvys Rodriguez-Abreu, Natividad Martínez-Banaclocha, David Aguiar, Joaquim Bosch-Barrera, R. Bernabé, M.A. Sala, Fernando Franco, Juana Oramas, A. Padilla, J. Casal, Mariano Provencio, Gretel Benítez, Remei Blanco, Ainhoa Hernández, Lourdes Gutiérrez, Enric Carcereny, O. Juan-Vidal, Ana Laura Ortega, R. López-Castro, Carlos Camps, M. Guirado, José Luis González-Larriba, Manuel Domine, Rosario García-Campelo, Bartomeu Massuti, and UAM. Departamento de Medicina

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Medicina, EGFR, non-small cell lung cancer (NSCLC), Logistic regression, Nomogram, Cancer Survivors, Non-small cell lung cancer, Surgical oncology, Carcinoma, Non-Small-Cell Lung, Internal medicine, Biomarkers, Tumor, Genetics, medicine, Humans, Lung cancer, RC254-282, Aged, Retrospective Studies, Models, Statistical, business.industry, Research, Advanced stage, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Chemoradiotherapy, Middle Aged, Prognosis, medicine.disease, Real life data, Predictive modeling, ErbB Receptors, Survival Rate, Nomograms, Mutation, Prognostic model, Female, Long survival, business, Follow-Up Studies
Abstract

Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiere, y los autores pertenecientes a la UAM, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations, Background There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. Methods EGFR mutated stage IIIB and IV NSCLC patients diagnosed between January 2009 and December 2017 included in the Spanish Lung Cancer Group (SLCG) thoracic tumor registry. Long-term survival was defined as being alive 24 months after diagnosis. A multivariable prognostic model was carried out using binary logistic regression and internal validation through bootstrapping. A nomogram was developed to facilitate the interpretation and applicability of the model. Results 505 of the 961 EGFR mutated patients identified in the registry were included, with a median survival of 27.73 months. Factors associated with overall survival longer than 24 months were: being a woman (OR 1.78); absence of the exon 20 insertion mutation (OR 2.77); functional status (ECOG 0–1) (OR 4.92); absence of central nervous system metastases (OR 2.22), absence of liver metastases (OR 1.90) or adrenal involvement (OR 2.35) and low number of metastatic sites (OR 1.22). The model had a good internal validation with a calibration slope equal to 0.781 and discrimination (optimism corrected C-index 0.680). Conclusions Survival greater than 24 months can be predicted from six pre-treatment clinicopathological variables. The model has a good discrimination ability. We hypothesized that this model could help the selection of the best treatment sequence in EGFR mutation NSCLC patients.

Published
2021
Full Text
View/download PDF

3. Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial

Author

Jorge García González, Alejandro Rodriguez-Festa, Bartomeu Massuti, M. Guirado, Silvia Calabuig-Fariñas, Ana Blasco, A. Insa, Sergio Vazquez Estévez, J. M. Jurado, Miguel Angel Molina-Vila, Manuel Cobo, Berta Hernandez, Margarita Majem, Oscar Juan Vidal, Pilar Diz, Ana Royuela, Atocha Romero, Beatriz García-Peláez, Javier Perez Altozano, Gretel Benítez, Ana López Martín, Santiago Viteri, Ana Collazo, Eloisa Jantus-Lewintre, Mariano Provencio, Carlos Garcia Giron, Patricia Cruz, Ana Laura Ortega, Joaquim Bosch-Barrera, and R. Bernabé

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, cell lung cancer, Intraclass correlation, Biopsy, DNA Mutational Analysis, non-small cell lung cancer (NSCLC), Tyrosine kinase inhibitor, Tyrosine-kinase inhibitor, Cohort Studies, circulating free DNA, T790M, 0302 clinical medicine, tyrosine kinase inhibitor, Gene Frequency, Osimertinib, Prospective cohort study, Càncer, non‐small‐cell lung cancer, Circulating free DNA, RC254-282, Research Articles, Sequence Deletion, Aged, 80 and over, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, High-Throughput Nucleotide Sequencing, non&#8208, General Medicine, DNA, Neoplasm, Exons, Middle Aged, ErbB Receptors, Epidermal growth factor receptor (EGFR), NGS, Non-small cell lung cancer (NSCLC), PCR, Tyrosine Kinase Inhibitor (TKI), circulating free DNA (cfDNA), osimertinib, 030220 oncology & carcinogenesis, osimertinib, NGS, Molecular Medicine, small&#8208, Female, Research Article, Adult, medicine.medical_specialty, medicine.drug_class, Sensitivity and Specificity, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, Genetics, medicine, Humans, Aged, non-small-cell lung cancer, business.industry, Epidermal growth factor receptor, Non invasive, epidermal growth factor receptor, medicine.disease, respiratory tract diseases, 030104 developmental biology, Egfr mutation, Pulmons, Mutation, business, Non-small-cell lung cancer
Abstract

Plasma samples from 72 EGFR‐mutant advanced NSCLC patients, collected upon progression to first‐line TKI, were analyzed by seven methodologies (two NGS‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods). Our study demonstrates a good to excellent agreement between methodologies and supports the use of liquid biopsies for therapy decision‐making., Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. Herein, seven methodologies including two next‐generation sequencing (NGS)‐based methods, three high‐sensitivity PCR‐based platforms, and two FDA‐approved methods were compared using 72 plasma samples, from EGFR‐mutant non‐small‐cell lung cancer (NSCLC) patients progressing on a first‐line tyrosine kinase inhibitor (TKI). NGS platforms as well as high‐sensitivity PCR‐based methodologies showed excellent agreement for EGFR‐sensitizing mutations (K = 0.80–0.89) and substantial agreement for T790M testing (K = 0.77 and 0.68, respectively). Mutant allele frequencies (MAFs) obtained by different quantitative methods showed an excellent reproducibility (intraclass correlation coefficients 0.86–0.98). Among other technical factors, discordant calls mostly occurred at mutant allele frequencies (MAFs) ≤ 0.5%. Agreement significantly improved when discarding samples with MAF ≤ 0.5%. EGFR mutations were detected at significantly lower MAFs in patients with brain metastases, suggesting that these patients risk for a false‐positive result. Our results support the use of liquid biopsies for noninvasive EGFR testing and highlight the need to systematically report MAFs.

Published
2021

4. 1326P Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive disease: Final results of a prospective multicenter study

Author

I. Barragan, J.F. Castilla Martinez, Marta Lloret, Gretel Benítez, J. Zafra, Pedro C. Lara, B. Salas, R. Chicas Sett, Daniel A Leon Rodriguez, J.L. Onieva, and Arturo Vera

Subjects
Radiation therapy, medicine.medical_specialty, Oncology, Multicenter study, business.industry, medicine.medical_treatment, Ablative case, Anti pd 1, Medicine, Hematology, Disease, Radiology, business
Published
2021
Full Text
View/download PDF

5. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

Author

Jesus Corral, Virginia Calvo, M. Biosca, Santiago Ponce-Aix, Marta C. Soares, Jon Zugazagoitia, Javier Pérez, Grupo de trombosis y cáncer Seom, Nerea Muñoz-Unceta, Manuel Domine, Maria Eugenia Olmedo, Carlos Aguado, Silverio Ros, Andrés Muñoz, Marta Carmona, Luis Paz-Ares, Imanol Martínez-Salas, Juan D Cacho, Ana María Luna, Laura Ortega-Morán, Carmen Salvador, Ana Blasco, Marcial García-Morillo, O. Juan-Vidal, Carme Font, Julia Martinez, A. Manzano, Francisco Aparisi, Manuel Sánchez-Cánovas, Júlio Oliveira, Rafael López, Lourdes Fernández, X. Mielgo, Gretel Benítez, Rafael Carrión, María Sereno, and Elisabeth Jiménez-Aguilar

Subjects
0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Population, ALK translocation, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins, Thromboembolism, ALK translocation, Advanced non–small cell lung cancer (NSCLC), Albumin, ROS1 rearrangement, Recurrent thrombosis, Thromboembolic event, Medicine, Humans, Prospective cohort study, education, Lung cancer, Aged, Aged, 80 and over, Gene Rearrangement, education.field_of_study, business.industry, Thromboembolic event, Albumin, Incidence (epidemiology), Incidence, Hazard ratio, Cancer, Middle Aged, Protein-Tyrosine Kinases, medicine.disease, Confidence interval, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, ROS1 rearrangement, Ambulatory, Female, Advanced non-small cell lung cancer (NSCLC), Recurrent thrombosis, business
Abstract

Introduction: Based on the high incidence of thromboembolic events (TEs) observed in lung adenocarcinomas with ALK translocations and taking into account the biological proximity of ROS1 and ALK, we conducted a retrospective analysis of patients with advanced lung carcinoma carrying rearrangements in ROS1 from 23 centres in Spain and one centre in Portugal. Methods: The main objective of the study was to analyse the incidence of TE in this population, looking for predictive risk factors, and its impact on overall survival. Results: A total of 58 patients were included. The incidence of TEs throughout the disease was 46.6% (n = 27) with a median follow-up of 19 months (range: 1-78 months) and a median overall survival of 52 months in the total population and 50 months for the patients presenting TEs, with a hazards ratio of 1.12 (95% confidence interval: 0.47-2.65) p = 0.78. The majority of the events were venous (n = 24; 89%) and occurred in the ambulatory setting (n = 18; 67%). Almost half of the patients (n = 13; 48%) presented the TE in the peri-diagnostic period. Conclusions: The high incidence of thrombosis, especially during the cancer diagnosis process, requires special attention from a clinician. Despite the limitations of such a small descriptive study, its results are in accordance with previously reported data. It would be important to design prospective studies of antithrombotic prophylaxis in this population because of their possible impact in reducing the risk of TEs. (C) 2020 Elsevier Ltd. All rights reserved.

Published
2020

6. Immuno-SABR Reboots the Immune Response in Patients with Metastatic NSCLC and Melanoma in Progression to Anti-PD-1 Therapy

Author

I. Morales, Daniel A Leon Rodriguez, Pedro C. Lara, J.F. Castilla Martinez, J. Zafra Martin, Gretel Benítez, R. Chicas Sett, and Marta Lloret

Subjects
Cancer Research, Radiation, business.industry, Melanoma, Anti pd 1, SABR volatility model, medicine.disease, Immune system, Oncology, Cancer research, Medicine, Radiology, Nuclear Medicine and imaging, In patient, business
Published
2020
Full Text
View/download PDF

7. P2.10-02 Smoking Habit in Lung Cancer in Spain

Author

Carlos Camps, Ana Ortega, E. Del Barco, A. Padilla, Joaquim Bosch-Barrera, F. Franco, J. De Castro Carpeno, Manuel Domine, Jose-Luis Gonzalez-Larriba, R. Garcia Campelo, Juana Oramas, Gretel Benítez, M. Guirado, R. Lopez Castro, Montserrat Domenech, R. Blanco, Enric Carcereny, S. Cerezo, R. Bernabé, David Aguiar, Delvys Rodriguez-Abreu, G. Huidobro, M. Provencio, M.A. Sala, B. Massuti, E. Cuadrado Albite, and R. de las Peñas

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, Smoking habit, business.industry, Internal medicine, medicine, Lung cancer, medicine.disease, business
Published
2019
Full Text
View/download PDF

8. P2.05-12 Analysis of Biomarkers in Lung Cancer in Spain

Author

Anna Estival, Thomas M. Moran, R. Garcia Campelo, M. Guirado, M.A. Sala, J.L. González Larriba, M. Provencio, B. Massuti, Gretel Benítez, Ana Ortega, Juana Oramas, R. Blanco, M. Lázaro, R. Lopez Castro, Manuel Domine, Beatriz Nuñez, Carlos Camps, A. Padilla, Delvys Rodriguez-Abreu, E. Del Barco, R. Bernabé, and Joaquim Bosch-Barrera

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, business, Lung cancer, medicine.disease
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results